Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/ TGF-β1/KLF6 signaling pathway in diabetic pulmonary fibrosis
- 1 June 2017
- journal article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 44, 70-77
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Fund of China (81273512, 81473209, 91439105)
This publication has 28 references indexed in Scilit:
- The Discovery of LOX-1, its Ligands and Clinical SignificanceCardiovascular Drugs and Therapy, 2011
- Integrating mechanisms of pulmonary fibrosisJournal of Experimental Medicine, 2011
- Pulmonary fibrosis: a possible diabetic complicationDiabetes/Metabolism Research and Reviews, 2011
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Patients Diagnosed With Diabetes Are at Increased Risk for Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, and Pneumonia but Not Lung CancerDiabetes Care, 2009
- Contribution of Epithelial-derived Fibroblasts to Bleomycin-induced Lung FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosisRespiratory Medicine, 2009
- TGF-β-induced EMT: mechanisms and implications for fibrotic lung diseaseAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrixProceedings of the National Academy of Sciences, 2006